JPRN-UMIN000000897已完成未知
A comparison of peginterferon ribavirin combination therapies for chronic hepatitis C - A comparison of peginterferon ribavirin combination therapies
niversity of Tokyo Department of Gastroenterology, Faculty of Medicine0 个研究点目标入组 320 人开始时间: 2007年11月17日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 320
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •The exclusion criteria are as follows: 1.liver disease such as autoimmune hepatitis, coinfection with hepatitis B, 2.severe renal disease, Ccr <50ml/min 3.poorly controlled heart disease 4.depression or psychosomatic disorders 5.Sho-saiko-to treatment within 30 days before interferon administration 6.pregnant or lactating women and women who may be pregnant 7.a man who can not avoid conception during administration of ribavirin and until 6 month after the end ribavirin treatment 8.drug allergy against interferon or ribavirin 9.allergy against biological drugs 10.no prior therapy of peginterferon in combination with ribavirin 11.on other clinical trial 12.any reason which medical doctor regard the patient as unsuitable for this test
研究者
相似试验
已完成
2 期
A comparison of peginterferon alfa-2a plus ribavirin and peginterferon alfa-2b plus ribavirin for. postmenopausal women. with chronic hepatitis type C : An open-label randomized controlled trial.Chronic hepatitis CJPRN-UMIN000001604Hiroshima liver study group80
已完成
不适用
Efficacy of pegylated interferon plus ribavirin lead-in therapy on telaprevir with pegylated interferon plus ribavirin therapy for aged patients with chronic hepatitis C genotype 1Chronic hepatitis CJPRN-UMIN000007329Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine410
已完成
不适用
Effect of pegylated interferon and ribavirin therapy on the QOL in the treatment of chronic hepatitis CJPRN-UMIN000003988Tokai University School of Medicine, Department of Internal Medicine, Division of Gastroenterology60
进行中（未招募）
不适用
Peginterferon alfa-2a and Ribavirin Combination Therapy in Patients with HBeAg-negative Chronic HBV Infection - PARC studyEUCTR2004-004736-30-ATErasmus MC122
进行中（未招募）
不适用
Peginterferon alfa-2a and Ribavirin Combination Therapy in Patients with HBeAg-negative Chronic HBV Infection - PARC studychronic HBeAg-negative hepatitis BEUCTR2004-004736-30-DEFoundation of Liver research122